TRADES
Latest Trades
4423
results found
FUND
DATE
ACTION
TICKER
COMPANY
SHARES
% of ETF
ARKG 20 Sep 2023 Buy TDOC TELADOC INC 57,862 0.0649
ARKG 20 Sep 2023 Buy SLGC SOMALOGIC INC 23,872 0.0030
ARKG 20 Sep 2023 Sell SDGR SCHRODINGER INC 6,842 0.0118
ARKG 20 Sep 2023 Buy RXRX RECURSION PHARMACEUTICALS 128,057 0.0569
ARKG 20 Sep 2023 Buy PACB PACIFIC BIOSCIENCES OF CALIF 85,256 0.0439
ARKG 20 Sep 2023 Buy NTLA INTELLIA THERAPEUTICS INC 18,722 0.0351
ARKG 20 Sep 2023 Buy DNA GINKGO BIOWORKS HOLDINGS INC 439,175 0.0432
ARKG 19 Sep 2023 Buy TDOC TELADOC INC 19,268 0.0216
ARKG 19 Sep 2023 Sell SDGR SCHRODINGER INC 2,533 0.0044
ARKG 19 Sep 2023 Buy RXRX RECURSION PHARMACEUTICALS 112,885 0.0509
ARKG 19 Sep 2023 Buy PACB PACIFIC BIOSCIENCES OF CALIF 77,543 0.0392
ARKG 19 Sep 2023 Sell NVDA NVIDIA CORP 16,897 0.3971
ARKG 19 Sep 2023 Buy NTLA INTELLIA THERAPEUTICS INC 30,414 0.0566
ARKG 19 Sep 2023 Buy DNA GINKGO BIOWORKS HOLDINGS INC 192,825 0.0188
ARKG 19 Sep 2023 Buy BEAM BEAM THERAPEUTICS INC 1,726 0.0022
ARKG 18 Sep 2023 Sell SDGR SCHRODINGER INC 10,099 0.0170
ARKG 18 Sep 2023 Buy RXRX RECURSION PHARMACEUTICALS 74,163 0.0324
ARKG 18 Sep 2023 Buy BEAM BEAM THERAPEUTICS INC 16,617 0.0213
ARKG 15 Sep 2023 Buy RXRX RECURSION PHARMACEUTICALS 118,176 0.0513
ARKG 15 Sep 2023 Buy BEAM BEAM THERAPEUTICS INC 7,356 0.0095
ARKG 14 Sep 2023 Buy SLGC SOMALOGIC INC 299 0.0000
ARKG 14 Sep 2023 Sell SDGR SCHRODINGER INC 998 0.0017
ARKG 14 Sep 2023 Buy RXRX RECURSION PHARMACEUTICALS 38,016 0.0165
ARKG 14 Sep 2023 Buy BEAM BEAM THERAPEUTICS INC 3,515 0.0045
ARKG 13 Sep 2023 Sell SDGR SCHRODINGER INC 12,376 0.0212
ARKG 13 Sep 2023 Buy BEAM BEAM THERAPEUTICS INC 30,419 0.0385
ARKG 12 Sep 2023 Buy SLGC SOMALOGIC INC 868 0.0001
ARKG 12 Sep 2023 Sell SDGR SCHRODINGER INC 3,085 0.0052
ARKG 12 Sep 2023 Buy RXRX RECURSION PHARMACEUTICALS 106,865 0.0441
ARKG 11 Sep 2023 Sell SDGR SCHRODINGER INC 52,743 0.0906
ARKG 11 Sep 2023 Buy RXRX RECURSION PHARMACEUTICALS 10,965 0.0045
ARKG 8 Sep 2023 Buy SLGC SOMALOGIC INC 38,208 0.0041
ARKG 8 Sep 2023 Buy PACB PACIFIC BIOSCIENCES OF CALIF 36,145 0.0191
ARKG 8 Sep 2023 Sell NVDA NVIDIA CORP 3,412 0.0787
ARKG 7 Sep 2023 Buy SLGC SOMALOGIC INC 3,422 0.0003
ARKG 7 Sep 2023 Buy PACB PACIFIC BIOSCIENCES OF CALIF 72,500 0.0382
ARKG 7 Sep 2023 Sell NVDA NVIDIA CORP 13,522 0.3023
ARKG 7 Sep 2023 Buy NRIX NURIX THERAPEUTICS INC 341,333 0.1498
ARKG 7 Sep 2023 Sell EXAS EXACT SCIENCES CORP 1,810 0.0071
ARKG 7 Sep 2023 Sell CELL PHENOMEX INC 94 0.0000
ARKG 7 Sep 2023 Buy BEAM BEAM THERAPEUTICS INC 3,972 0.0047
ARKG 6 Sep 2023 Buy SLGC SOMALOGIC INC 132,731 0.0132
ARKG 6 Sep 2023 Buy PACB PACIFIC BIOSCIENCES OF CALIF 110,058 0.0592
ARKG 6 Sep 2023 Buy NVTA INVITAE CORP 466,119 0.0195
ARKG 6 Sep 2023 Sell EXAS EXACT SCIENCES CORP 8,074 0.0325
ARKG 6 Sep 2023 Buy BEAM BEAM THERAPEUTICS INC 152 0.0002
ARKG 5 Sep 2023 Buy PACB PACIFIC BIOSCIENCES OF CALIF 54,764 0.0289
ARKG 5 Sep 2023 Sell NVDA NVIDIA CORP 4,080 0.0944
ARKG 5 Sep 2023 Sell CELL PHENOMEX INC 188 0.0000
ARKG 5 Sep 2023 Buy BEAM BEAM THERAPEUTICS INC 3,717 0.0041
ARKG 1 Sep 2023 Sell CELL PHENOMEX INC 4,016 0.0002
ARKG 31 Aug 2023 Buy NTLA INTELLIA THERAPEUTICS INC 6,699 0.0120
ARKG 31 Aug 2023 Sell CELL PHENOMEX INC 3,037 0.0001
ARKG 31 Aug 2023 Sell CDXS CODEXIS INC 92 0.0000
ARKG 31 Aug 2023 Buy ACCD ACCOLADE INC 43,619 0.0280
ARKG 30 Aug 2023 Buy NTLA INTELLIA THERAPEUTICS INC 1,401 0.0025
ARKG 30 Aug 2023 Sell CDXS CODEXIS INC 572 0.0000
ARKG 29 Aug 2023 Sell CELL PHENOMEX INC 1,000 0.0000
ARKG 29 Aug 2023 Sell CDXS CODEXIS INC 8,500 0.0007
ARKG 28 Aug 2023 Buy NTLA INTELLIA THERAPEUTICS INC 972 0.0018
ARKG 28 Aug 2023 Sell CELL PHENOMEX INC 8,900 0.0004
ARKG 28 Aug 2023 Sell CDXS CODEXIS INC 110,596 0.0094
ARKG 28 Aug 2023 Buy ACCD ACCOLADE INC 7,983 0.0052
ARKG 25 Aug 2023 Buy NTLA INTELLIA THERAPEUTICS INC 7,729 0.0146
ARKG 25 Aug 2023 Buy ACCD ACCOLADE INC 12,573 0.0082
ARKG 24 Aug 2023 Buy RXRX RECURSION PHARMACEUTICALS 132,235 0.0581
ARKG 24 Aug 2023 Buy NVTA INVITAE CORP 237,456 0.0103
ARKG 24 Aug 2023 Sell NVDA NVIDIA CORP 3,952 0.0942
ARKG 24 Aug 2023 Buy NTLA INTELLIA THERAPEUTICS INC 34,226 0.0630
ARKG 24 Aug 2023 Buy CRSP CRISPR THERAPEUTICS AG 7,447 0.0180
ARKG 24 Aug 2023 Sell CELL PHENOMEX INC 210,694 0.0097
ARKG 24 Aug 2023 Buy ACCD ACCOLADE INC 89,823 0.0573
ARKG 23 Aug 2023 Buy RXRX RECURSION PHARMACEUTICALS 5,041 0.0023
ARKG 23 Aug 2023 Buy NTLA INTELLIA THERAPEUTICS INC 10,402 0.0200
ARKG 23 Aug 2023 Sell CELL PHENOMEX INC 1,428,197 0.0675
ARKG 23 Aug 2023 Sell CDXS CODEXIS INC 599,478 0.0544
ARKG 22 Aug 2023 Buy RXRX RECURSION PHARMACEUTICALS 62,867 0.0279
ARKG 22 Aug 2023 Buy NTLA INTELLIA THERAPEUTICS INC 66 0.0001
ARKG 22 Aug 2023 Buy CRSP CRISPR THERAPEUTICS AG 211 0.0005
ARKG 22 Aug 2023 Sell CELL PHENOMEX INC 350,690 0.0166
ARKG 22 Aug 2023 Sell CDXS CODEXIS INC 249,538 0.0220
ARKG 22 Aug 2023 Buy ADPT ADAPTIVE BIOTECHNOLOGIES 176,072 0.0565
ARKG 21 Aug 2023 Buy RXRX RECURSION PHARMACEUTICALS 37,638 0.0169
ARKG 21 Aug 2023 Buy NTLA INTELLIA THERAPEUTICS INC 4,486 0.0086
ARKG 21 Aug 2023 Buy DNA GINKGO BIOWORKS HOLDINGS INC 56,042 0.0047
ARKG 21 Aug 2023 Buy CRSP CRISPR THERAPEUTICS AG 7,017 0.0170
ARKG 21 Aug 2023 Sell CELL PHENOMEX INC 249,507 0.0121
ARKG 21 Aug 2023 Sell CDXS CODEXIS INC 249,538 0.0222
ARKG 21 Aug 2023 Buy ADPT ADAPTIVE BIOTECHNOLOGIES 32,165 0.0102
ARKG 21 Aug 2023 Buy ACCD ACCOLADE INC 13,950 0.0092
ARKG 18 Aug 2023 Sell SDGR SCHRODINGER INC 44,668 0.0774
ARKG 18 Aug 2023 Buy RXRX RECURSION PHARMACEUTICALS 16,319 0.0072
ARKG 18 Aug 2023 Buy DNA GINKGO BIOWORKS HOLDINGS INC 34,167 0.0028
ARKG 18 Aug 2023 Sell CDXS CODEXIS INC 1,416,591 0.1180
ARKG 18 Aug 2023 Buy ADPT ADAPTIVE BIOTECHNOLOGIES 45,133 0.0142
ARKG 17 Aug 2023 Sell SDGR SCHRODINGER INC 48,019 0.0825
ARKG 17 Aug 2023 Buy RXRX RECURSION PHARMACEUTICALS 37,868 0.0163
ARKG 17 Aug 2023 Buy NTLA INTELLIA THERAPEUTICS INC 1,341 0.0025
ARKG 17 Aug 2023 Sell EXAS EXACT SCIENCES CORP 10,868 0.0461
ARKG 17 Aug 2023 Buy DNA GINKGO BIOWORKS HOLDINGS INC 33,272 0.0027
Latest Blogs
ARK by Cathie Wood is still suffering a year after its apex.

Cathie Wood's flagship exchange-traded fund hit an all-time high in February of this year. Her preferred disruptive-tech chasing strategy may still be in for a lot of suffering after a year and a 53 percent fall.

After a dramatic decline last month, the ARK Innovation ETF (ticker: ARKK) has steadied off - it's practically flat in February – but the headwinds surrounding its speculative growth picks are just becoming more vital. Many businesses that thrived during the pandemic are being hammered by the economic reopening, not only because yields are rising as investors prepare for the US Federal Reserve to raise interest rates, which is terrible news for unprofitable businesses, but also because the economic reopening is hammering many of the businesses that thrived during the pandemic.

Roku, Teladoc, and Zoom, all winners in the work-from-home era, have had their stock prices plummet by as much as 74% in the past year.

Short bets against ARK, according to IHS Markit data, hit a fresh high of 11.4 percent of outstanding shares this week. The Tuttle Capital Short Innovation ETF (SARK), which beats the ARK, now has assets worth more than $US300 million ($416 million).

"Those equities are supported by speculation, and speculation pays less well when the Fed raises rates," said Brent Schutte, chief investment strategist at Northwestern Mutual Wealth Management Co. "Much of what's happening in the market reminds me of what happened in the late 1990s when market segments were bid up to levels based on future assumptions."

Because its price chart resembles that of the Nasdaq index of technology businesses from more than two decades ago, analogies to that period and the dot-com implosion that followed are becoming more common in discussions of ARK.

"Today marks the 253rd trading day from ARK's all-time high," Jessica Rabe, co-founder of DataTrek Research, wrote in a Tuesday note, "while the Nasdaq was down 60% from its dot-com bubble top on the same day in 2001."

"If 2000/2001 analog holds, we should see ARK continuing to fall over the following three weeks. The Nasdaq dropped 18.7% in the next 16 trading days "recent."

Net flows are positive.

The better news for investors and Ms. Wood is that there may be some immediate respite. The Nasdaq rose 41% in six weeks in 2001 before falling.

The ARK Investment Management did not respond to a request for comment.

Most of ARK's $US15 billion asset loss has been attributed to bad performance, a plus for the company. Since the fund achieved an intraday high of $US159.70 a year ago this week, investors have withdrawn only around $US465 million, and ARK's net flows this year are positive despite a more than 20% drop.

This exceptional loyalty prevents a worsening situation and allows Wood's approach to recovering. The star fund manager has consistently emphasized that her funds have a five-year investment horizon and that she believes in many good options.

Mr. Schutte, on the other hand, says the drop is understandable because several of the company's biggest bets, such as Teladoc and Zoom, are becoming less significant as COVID-19 approaches.

"During the pandemic, there were a lot of questions about what would happen to society and how we'd go about our lives," he added.

"You drew in new investors who wanted to know "what are the upcoming themes I should invest in?" I believe you got a washout of it as well."

On Friday, Cathie Wood sold $148.9 million worth of Palantir stock, halving her exposure.

Ark Investment Management, run by Cathie Wood, sold more Palantir Technologies Inc PLTR -6.39 percent shares on Friday, cutting its stake in the Peter Thiel-backed company.

According to Friday's closing price, the famous investment management firm sold 13.5 million shares of the big data company, valued at $148.9 million.

Palantir's stock fell 6.4 percent to $11.02 per share on Friday. The stock has lost 16% of its value in the last week.

Before Friday's trade, Ark Invest held 25.53 million shares in Palantir, suggesting that the famous stock picker had trimmed over 52 percent of its total keeping a day later.

After the business disclosed lower-than-expected fourth-quarter earnings before the market opened on Thursday, Ark Invest, located in St. Petersburg, California, dumped shares in Palantir for the second time.

The software firm, well-known for its work with government organizations, posted earnings of 2 cents per share, falling short of the analyst consensus of 4 cents. The company recorded quarterly revenues of $432.87 million, higher than the $417.69 million predicted by analysts.

Palantir's stock had been sold for 4.77 million shares by the investment firm the day before.

All six of Ark Invest's active exchange-traded funds own Palantir stock, including the flagship Ark Innovation ETF ARKK -4.88 percent.

Before the recent sell-off, Ark Invest had been stockpiling Palantir shares for months.

Cathie Wood appeared on television to defend her ARK funds' dismal performance. It didn't go quite as planned.

The Ark Innovation ETF (ARKK), Cathie Wood's flagship fund, is down 30% year to date and more volatile than almost any other fund on the market. On CNBC's Halftime Report, Wood jumped at the chance to defend the fund and its deflated price, which is currently $68.80, down from $155 a year ago.

"We've seen a significant decline," Wood said, adding, "We feel innovation is at bargain basement zone." Even though her ETF was underperforming, she emphasized that her companies were still "very inexpensive" and that the current fund loss was temporary. When the call's 40 free minutes were finished, Zoom gave her an extra 10 minutes to complete the interview.

Having Zoom check to see whether she was "running out of time?" Wood, who has been aggressively buying up shares in Zoom and other IT firms that have fallen from their pandemic highs, was unhappy. Zoom, like Wood's other significant tech holdings, Teladoc Health, Roku, and Roblox, is down 20% to 40% year to date as investors worry about rising interest and inflation rates.

However, a significant chunk of the interview was devoted to a personal assault on Cathie Wood, who was named the most excellent stock picker in 2020 by Bloomberg's then-Editor-in-Chief Matthew Winkler after correctly forecasting that Tesla will one day be valued at more than $1 trillion.

Wood bluntly ignored Tuttle Capital Management's Short Innovation ETF (SARK), which tracks the inverse performance of ARKK using swaps contracts for the sole purpose of betting against Cathie Wood's selections. "They're not conducting any research." She explained, "All they're doing is shorting innovation."

Of course, SARK is betting against Cathie Woods, not on innovation. "Well, we stand for invention," Wood responded. The SARK ETF has gained 55 percent since its debut, whereas the ARKK ETF has declined by 42 percent.

Tuttle Capital Management CEO Matthew Tuttle chimed in on the SARK ETF, calling it a "tool" for investors. According to SARK, "to convey a negative view of the market, innovative enterprises, the current rising rate environment, or a [specific] portfolio manager if they wish." "It's un-American not to have options in the marketplace," Tuttle told Insider on Thursday.

In any event, Wood is making progress. Her main concern currently is bearish calls on her ETF. "Our major concern is that our investors convert temporary losses into long-term losses," Wood continued.